Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.

European journal of haematology - 1 Apr 2016

Mela Osorio María J, Ferrari Luciana, Goette Nora P, Gutierrez Marina I, Glembotsky Ana C, Maldonado Ana C, Lev Paola R, Alvarez Clarisa, Korin Laura, Marta Rosana F, Molinas Felisa C, Heller Paula G

Abstract excerpt

BACKGROUND: Anagrelide represents a treatment option for essential thrombocythemia, although its place in therapy remains controversial. AIM: To assess the impact of mutational status in response rates and development of adverse events during long-term use of anagrelide. METHODS: We retrospectively evaluated 67 patients with essential thrombocythemia treated with anagrelide during 68 (4-176) months. RESULTS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Calreticulin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Platelet Aggregation Inhibitors

Share to Primary Myelofibrosis

Share to Quinazolines

Share to Receptors, Thrombopoietin

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 26119186
DOI: 10.1111/ejh.12614

Genes

CALR
MPL
JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.PMID 26119186Read ↗

Anagrelide and Mutational Status in Essential Thrombocythemia.Semantic proximity Read ↗

Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.Semantic proximity Read ↗

Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia.Semantic proximity Read ↗

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.Semantic proximity Read ↗

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.Semantic proximity Read ↗

One thousand patients with essential thrombocythemia: the Mayo Clinic experience.Semantic proximity Read ↗

Anagrelide and the CALR mutation allele burden in essential thrombocythemia.Semantic proximity Read ↗

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients.Semantic proximity Read ↗

Essential thrombocythemia treatment algorithm 2018.Semantic proximity Read ↗

Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.Semantic proximity Read ↗

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.Semantic proximity Read ↗

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.